Correspondence 0001437749-23-002806 from SAB Biotherapeutics, Inc. (SABS, SABSW) (CIK 0001833214) (SABS)
SAB Biotherapeutics, Inc. (SABS, SABSW) (CIK 0001833214)
Date: Feb. 8, 2023 · CIK: 0001833214 · Accession: 0001437749-23-002806
AI Filing Summary & Sentiment
File numbers found in text: 333-269565
Letter
sabs20230208_corresp.htm
February 8, 2023
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jason Drory
RE:
SAB Biotherapeutics, Inc.
Registration Statement on Form S-3
File No. 333-269565
Filed February 3, 2023
In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, February 10, 2023 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable.
Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
SAB Biotherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm sabs20230208_corresp.htm February 8, 2023 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory RE: SAB Biotherapeutics, Inc. Registration Statement on Form S-3 File No. 333-269565 Filed February 3, 2023 In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, SAB Biotherapeutics, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, February 10, 2023 at 5:00 p.m., Eastern Time, or as soon as thereafter practicable. Please call Ilan Katz of Dentons US LLP at (212) 632-5556 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, SAB Biotherapeutics, Inc. /s/ Eddie J. Sullivan Eddie J. Sullivan Chief Executive Officer cc: Ilan Katz, Dentons US LLP